Trial Profile
Efficacy of aflibercept in resistant neovascular age-related macular degeneration (nAMD) patients who had been treated and failed prior bevacizumab or ranibizumab injections.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 28 Aug 2017 New trial record